What is the appropriate next treatment for a patient with persistent diarrhea after completing antibiotic therapy for Clostridioides difficile infection?

Treatment of Persistent Diarrhea After C. difficile Antibiotic Therapy

The next step depends critically on whether this represents true treatment failure/recurrence versus post-infectious symptoms, but for confirmed recurrent C. difficile infection after initial treatment, you should prescribe either a tapered vancomycin regimen OR fidaxomicin, followed by consideration of fecal microbiota-based therapy to prevent further recurrences 1.

Initial Assessment: Distinguish True Recurrence from Post-Infectious Symptoms

Before escalating therapy, you must determine what you're actually treating:

• Do NOT routinely test for cure - stool testing should only be performed if diarrhea is persistent or worsening 1
• If testing is performed and positive with ongoing symptoms within 8 weeks of completing therapy, this represents a first recurrence (second CDI episode) 1
• Consider that up to 25% of patients develop post-infectious IBS-like symptoms after treated CDI, which represents persistent inflammation rather than ongoing infection 2, 3
• Investigate alternative causes if symptoms persist despite appropriate anti-CDI treatment 4

Key Clinical Pitfall

Persistent diarrhea correlates with intestinal inflammation, NOT bacterial burden 3. Fecal cytokines (IL-8, lactoferrin) predict treatment failure better than C. difficile load, meaning some patients have ongoing symptoms from inflammation rather than active infection requiring more antibiotics.

Treatment Algorithm for Confirmed First Recurrence

First-Line Options (Choose One):

Option 1: Fidaxomicin

• 200 mg orally twice daily for 10 days
• Preferred due to lower recurrence rates 1
• Major barrier: insurance coverage challenges (82% of clinicians report this) 5

Option 2: Vancomycin Taper

• Start: 125 mg orally 4 times daily × 10-14 days
• Then: 125 mg twice daily × 7 days
• Then: 125 mg once daily × 7 days
• Then: 125 mg every 2-3 days × 2-8 weeks 1, 6
• More accessible and acceptable alternative 1

Critical Point: Metronidazole should NOT be used for recurrent CDI due to neurotoxicity and hepatotoxicity risks with repeated courses 6.

Preventing Further Recurrences

After treating the first recurrence, you MUST assess recurrence risk and strongly consider microbiota restoration therapy 1:

Indications for Fecal Microbiota-Based Therapy:

1. After second recurrence (third CDI episode) - this is mandatory; offer FMT or FDA-approved products 4, 1

2. Consider earlier (after first recurrence or even initial infection) if:

   • High risk for recurrence (age >75, severe disease, ongoing antibiotics)
   • Initial episode was particularly severe or difficult to treat
   • Patient had fulminant disease 1

Available Microbiota Restoration Options:

• Fecal microbiota spores, live-brpk (Vowst) - available to 30% of clinicians 5
• Fecal microbiota, live-jslm (Rebyota) - available to 36% of clinicians 5
• Conventional FMT - 48% have access to donor stool FMT 5
• Use universal donors preferred over related donors 4
• Frozen FMT preferred over fresh 4

Timing of FMT:

• Must be preceded by at least 10 days of appropriate antibiotic treatment 4
• Offer repeat FMT if initial attempt fails 4
• Follow patients for at least 8 weeks post-FMT to assess efficacy 4

Alternative Strategy: Suppressive Vancomycin

If microbiota-based therapies are unavailable or contraindicated:

Prolonged suppressive vancomycin 125 mg once daily may be considered for 1:

• Multiple recurrent episodes
• Patients not candidates for FMT (severe immunocompromise, limited life expectancy)
• Ongoing/frequent systemic antibiotics
• Failed multiple FMT courses

Special Considerations

Severe or Fulminant Disease Not Responding to Initial Therapy:

If the patient has severe disease (WBC ≥15,000 or creatinine ≥1.5× baseline) or fulminant disease (shock, ileus, megacolon) that isn't improving:

• Consider FMT earlier - within 2-5 days of initiating treatment 7, 4
• Requires multidisciplinary management 7, 1
• Use multi-dose FMT via colonoscopy/sigmoidoscopy with fresh donor stool 1
• Continue suppressive vancomycin until final outpatient FMT can be administered 1

Contraindications to FMT:

• Bowel perforation or obstruction 7
• Severe immunocompromise 7
• Known anaphylactic food allergy 4

Adjunctive Measures:

• Evaluate PPI use - discontinue if no legitimate indication 1
• Counsel against unnecessary antibiotics 1
• Do NOT use cholestyramine concurrently with vancomycin/fidaxomicin 1
• Do NOT use probiotics for prevention 1
• Encourage high-fiber diet with fruits/vegetables to restore microbiota 1

IBD Patients:

Inform patients with inflammatory bowel disease about small risk of disease flare after FMT 4.